Belatacept in De Novo Heart Transplantation (NCT04477629)
Belatacept in De Novo Heart Transplantation - Pilot Study
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine if Belatacept is safe to give to adult heart transplant recipients. Belatacept (NULOJIX) is an anti-rejection medication that is available through a prescription from a doctor. In this research study, belatacept is being used in an investigational manner (not for the purpose that it is approved for).
Who can join: Review the eligibility criteria below.
Location: NYU Langone Health — New York, New York
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- NYU Langone Health — New York, New York
- Columbia University — New York, New York
📞 Contact the Study Coordinator
Phone: (646) 457-0987
Email: Andrea.Kim@nyulangone.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Heart Transplantation
- Precise Cooler for Donor Heart Transport — Los Angeles, California
Explore by condition: All Heart Transplantation clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.